Pseudomonas Aeruginosa Infection Management

Introduction to Treatment

The European Respiratory Society recommends maintenance therapy with daily inhaled antibiotics (colistin or tobramycin) or a month-on/month-off regimen of tobramycin, as well as regular treatment courses of intravenous antipseudomonal antibiotics 3-4 times yearly 1
Home therapy has several advantages, including maintenance of normal activity, school/work attendance, reduced hospitalization costs, and earlier antibiotic intervention, but requires patient/caregiver education, first dose under medical supervision, 24-hour telephone assistance, and regular monitoring 1
Proper nebulizer hygiene and technique are essential, including cleaning and drying nebulizers after each use and discharging exhaled antibiotics through a tube to outside air or trapping in a filter 1, 2

The European Respiratory Society recommends separating CF patients with and without P. aeruginosa infection, decontaminating environmental reservoirs, and hand disinfection for patients and healthcare personnel to prevent the spread of infection 1

Eradication of mucoid P. aeruginosa from CF airways in chronic infection is virtually impossible, and the focus should be on suppression rather than eradication 1
Sputum may impair uniform deposition of antibiotics and decrease therapeutic effects, so consider mucolytic agents before antibiotic administration 1
Chronic P. aeruginosa infection leads to more frequent exacerbations, faster decline in pulmonary function, and increased morbidity and mortality, as stated by the European Respiratory Society 1

Combination therapy with an antipseudomonal β-lactam plus another agent is recommended when Pseudomonas is suspected or documented 1
Early treatment of P. aeruginosa colonization with combination therapy, including inhaled antibiotics and oral ciprofloxacin, is recommended, as stated by the European Cystic Fibrosis Society 2
For acute exacerbations, combination antibiotic therapy directed against P. aeruginosa, increased airway clearance therapy, and continuation of chronic therapies for maintenance of lung health are recommended, as suggested by the American Thoracic Society 3

Regular monitoring with monthly or at least quarterly microbiological cultures is recommended, as suggested by the European Cystic Fibrosis Society 2
Signs and symptoms of an acute exacerbation include increased cough and sputum production, changes in sputum characteristics, decreased pulmonary function, increased respiratory rate, fever, and decreased appetite and weight loss, as described by the American Thoracic Society 3

CF patients with CF-related diabetes have a greater frequency and severity of pulmonary exacerbations, as reported by the European Association for the Study of Diabetes 4
Early colonization of P. aeruginosa can occur in the first year of life in cystic fibrosis patients, and without treatment, 80% progress to chronic infection within 7 years, leading to significantly reduced life expectancy 1
Untreated P. aeruginosa infections result in accelerated FEV1 decline, structural lung damage, chronic infection establishment, respiratory failure, and increased mortality in cystic fibrosis patients 1
The European Respiratory Society guidelines provide strong evidence that untreated P. aeruginosa infections lead to significantly reduced survival rates in cystic fibrosis patients 1